Ray KK, et al. - In the ODYSSEY DM-DYSLIPIDEMIA trial, the researchers pursued a comparison of alirocumab, a proprotein convertase subtilisin-kexin type 9 inhibitor, with usual care (UC) in individuals with type 2 diabetes (T2DM) and mixed dyslipidaemia not optimally managed by maximally tolerated statins. The randomized population included four hundred thirteen individuals. According to the findings obtained, alirocumab showed superiority to UC in non-HDL cholesterol reduction and was generally well tolerated in individuals with T2DM and mixed dyslipidaemia on a maximally tolerated statin.